Figure 3
Figure 3. Morgana is underexpressed in aCML patients’ BM. (A) Morgana IHC staining on normal human BM. (B) Western blot analysis of morgana in different BM populations and in total mouse BM. (C) Morgana fluorescence intensity in different mouse BM populations as assessed by flow cytometry. (D) Morgana IHC staining on BM biopsies of 4 aCML patients. The scale bar = 100 μm. (E) P-MLC2 IHC staining on a BM biopsy from an aCML patient expressing low morgana level (case 1) and a case of MDS/MPD expressing normal morgana level (case 6). The scale bar = 100 μm. The graph shows the IHC quantification of P-MLC2. (F) Percentages of apoptosis in BM cells derived from morgana+/+ and morgana+/–-diseased mice after 48 hours of treatment with fasudil (10 μM). *P < .05.

Morgana is underexpressed in aCML patients’ BM. (A) Morgana IHC staining on normal human BM. (B) Western blot analysis of morgana in different BM populations and in total mouse BM. (C) Morgana fluorescence intensity in different mouse BM populations as assessed by flow cytometry. (D) Morgana IHC staining on BM biopsies of 4 aCML patients. The scale bar = 100 μm. (E) P-MLC2 IHC staining on a BM biopsy from an aCML patient expressing low morgana level (case 1) and a case of MDS/MPD expressing normal morgana level (case 6). The scale bar = 100 μm. The graph shows the IHC quantification of P-MLC2. (F) Percentages of apoptosis in BM cells derived from morgana+/+ and morgana+/–-diseased mice after 48 hours of treatment with fasudil (10 μM). *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal